PsilodexMedication × psilocybin
Your list
Supplements and over the counter
Brand names
—
Reviewed 2026-10-02

Quercetin

psilodex.org/m/quercetin · data v2026.10.02

Clinical contraindication
None listed
No clinical contraindication identified.
Best available evidence
Mechanism only
Half-life
Not recorded
Named in state rules?
CONot named
ORNot named
NMPending
Cite asPsilodex: quercetin · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Th

Quercetin inhibited UGT1A9-mediated glucuronidation in vitro; UGT1A9 is one route of psilocin clearance. Clinical relevance at supplement doses is unknown. No psilocybin-specific data.

Human data with psilocybin
None known: no published human data with psilocybin
Evidence types on this record
ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

1 listed · counted on reports
UGT inhibition (theoretical effect on psilocin levels)
Inhibits UGT enzymes (glucuronidation), the main route by which the body clears psilocin. In theory this could raise psilocin levels or lengthen the effect. Sources [1]

03 State rules

Plain-language summary · official text governs
CO4 CCR 755-1
Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

3
  1. Wu F, Wang Y, Mei Q, et al. UGTs-mediated metabolic interactions contribute to enhanced anti-inflammation activity of Jinhongtang. J Ethnopharmacol 2023;304:116016. — quercetin Ki 2.84 uM for UGT1A9
  2. Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
  3. Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

  • v2026.10.02First published.
  • 2026-10-02Last reviewed against its sources.

Report an error in this record →

Before you startTerms v2026-10-01

What Psilodex is, and isn't.

  1. 01Psilodex summarizes published evidence and public state rules. It does not decide whether you can safely use psilocybin or take part in services, and it is not medical advice.
  2. 02Starting, stopping, or changing a medication is the prescriber's decision. Bring the report to them.
  3. 03Your searches and list stay in this browser and are not sent to us. Opening a medication's page is an ordinary web request, so our hosting providers see which page was opened. What we can and can't see.

In an emergency, call 911. For a mental health crisis, call or text 988. Full terms and privacy.